RecruitingPancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaPancreas Cancer
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is designed to explore the efficacy and safety of surufatinib combined with camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in unresectable advanced or metastatic pancreatic cancer.
Sponsor: Chinese PLA General Hospital
You may qualify if…
- ✓ 1. Have fully understood this study and voluntarily signed the informed consent form;
- ✓ 2. Patients with histologically or cytologically confirmed unresectable, locally advanced, or metastatic pancreatic ductal adenocarcinoma;
- ✓ 3. Age 18-75 years old (inclusive);
- ✓ 4. No prior systemic therapy for advanced pancreatic carcinoma;
- ✓ 5. ECOG PS 0-1;
- ✓ 6. Must have at least one measurable lesion, with the longest diameter of at least 10 mm as measured by spiral CT scan, or at least 20 mm as measured by conventional CT scan (according to Response Evaluation Criteria in Solid Tumors, i.e. RECIST v1.1);
- ✓ 7. Expected survival ≥ 3 months;
- ✓ 8. The functions of vital organs meet the following requirements (the use of any blood components and cell growth factors within \*14 days before enrollment is not allowed):
You may not qualify if…
- ✕ 1. Unable to comply with the study protocol or study procedures;
- ✕ 2. Previously received treatment with VEGFR inhibitors, or previously used ICI treatment;
- ✕ 3. Participating in or having participated in other drug clinical trials within 4 weeks prior to enrollment;
- ✕ 4. Have received transfusion therapy, blood products, and hematopoietic factors, such as albumin and G-CSF, within 14 days prior to enrollment;
- ✕ 5. Brachytherapy (radioactive seed implantation) within 60 days prior to enrollment;
- ✕ 6. Have received other systemic anti-tumor treatments within 4 weeks prior to enrollment, including chemotherapy, signal transduction inhibitors, hormone therapy, and immunotherapy;
- ✕ 7. Have received any surgery or invasive treatment or procedure within 4 weeks prior to enrollment (excluding intravenous catheterization, paracentesis drainage, etc.);
- ✕ 8. Undergone major surgery within 60 days prior to enrollment or the surgical incision has not completely healed;
Source: ClinicalTrials.gov · NCT05218889 · last updated 2024-12-31